In a report released today, Dev Weerasuriya from Berenberg Bank reiterated a Buy rating on Progyny (PGNY – Research Report), with a price target of $58.00. The company’s shares closed last Monday at $26.40, close to its 52-week low of $26.28.
According to TipRanks.com, Weerasuriya has 0 stars on 0-5 stars ranking scale with an average return of -24.7% and a 15.4% success rate. Weerasuriya covers the Technology sector, focusing on stocks such as Health Catalyst, Accolade, and Omnicell.
Currently, the analyst consensus on Progyny is a Moderate Buy with an average price target of $58.50.
Progyny’s market cap is currently $2.43B and has a P/E ratio of 47.57.
Based on the recent corporate insider activity of 135 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PGNY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.
Read More on PGNY:
- Aurora Mobile’s Subsidiary SendCloud Partners with Leading Content Provider Zhihu to Jointly Promote Customer Reach
- Emovis UK Chooses Progress to Provide Full Network Visibility, Eliminating Cyber Blind Spots
- Friendable’s Fan Pass Live and 360 Indie Music Artist Offering Announces Key Metrics & Market Penetration Data to Support Its Next Phase of Expansion, Exposure, & Service Offerings, to Include VIP Backstage Streaming, Metaverse Land & More
- Booz Allen (BAH) Received its Third Buy in a Row
- Wall Street Analysts Are Bullish on Top Technology Picks